Background. Albuminuria and elevated C-reactive protein (CRP) levels are common manifestations of many inflammatory diseases. Cardiovascular-based drugs, with secondary anti-inflammatory actions, such as angiotensin-converting enzyme-inhibitors are able to reduce both proteinuria and CRP levels, raising the question of whether CRP directly influences the processes that result in proteinuria. As proteinuria is thought to be induced as a result of podocyte dysfunction, we investigated whether there is a pathomechanistic link with CRP. Methods. Podocytes were analysed for evidence of endogenous CRP production in response to inflammatory agents. In addition, they were incubated in the presence of various concentrations of exogenous CRP and analysed for evidence of a response to treatment. Results. Our results demonstrated that inflammatory agents such as macrophage-conditioned medium and interleukin-1b induced the expression of CRP messenger RNA in podocytes. However, they were unable to induce CRP protein. Stimulation of podocytes with exogenous CRP demonstrated that 10 lg/mL CRP induced a low but significant level of interleukin-6 secretion. Tumour necrosis factor a, however, was not detected. CRP did up-regulate the expression of the slit diaphragm proteins nephrin and CD2AP, as well as the structural proteins ezrin and podocalyxin-like protein-1, proteins known to be involved in signalling via the phosphotidylinositol-3 (PI-3) kinase pathway. CRP exposure reduced caspase-3 enzyme activity and up-regulated the expression of the anti-apoptotic protein Bcl-2. In the presence of the PI-3 kinase inhibitor LY294002, the ability of CRP to suppress caspase-3 activity was significantly reduced. Conclusions. Taken together, these data suggest that rather than inducing podocyte damage, CRP may be a survival factor for podocytes by maintaining their structural integrity and initiating a survival cascade, which may facilitate podocyte recovery from injury.
Introduction
C-reactive protein (CRP) is a highly conserved prototypical acute phase reactant, which functions to facilitate the innate immune system and limit tissue damage in autoimmune reactions [1, 2] . Consistent with this role, plasma concentrations of CRP can increase from basal levels of 1 lg/mL (median concentration 0.8 lg/mL) to >1000 lg/mL within 24-48 h in response to acute inflammation or injury and decrease rapidly to baseline levels following resolution of disease. However, it is the chronically raised levels of CRP (>10 lg/mL) that are indicative of an underlying pathology. It is commonly accepted that raised CRP levels are characteristic of atherosclerotic cardiovascular disease, an inflammatory disease of vessel walls. Evidence suggests that such cardiovascular disease occurs, at least in part, as a result of CRP-induced endothelial cell dysfunction. These effects include increased expression of adhesion molecules [3] , decay-accelerating factor [4] and secretion of chemokines [5] , reduced expression of eNOS [6] , reduced secretion of von Willebrand factor [7] , inhibition of cell proliferation, reduced cell viability [8] and increased apoptosis [9] . However, some of these effects have been ascribed to lipopolysaccharide (LPS) and/or azide, agents known to be present in commercial CRP preparations [10, 11] Albuminuria, like raised CRP levels, is often found in association with inflammatory disease and is also thought to be a consequence of the generalized endothelial dysfunction that occurs throughout the vasculature. Agents such as renin angiotensin system blockers [12] , HMG-CoA reductase inhibitors [13, 14] and thiazolidinediones [15, 16] have been shown, in addition to their specific pharmacological actions, to reduce CRP levels, proteinuria and cardiovascular risk. Although the mechanism of these effects has not been fully delineated these agents are known to have well-described anti-inflammatory properties.
Since proteinuria results from podocyte dysfunction, this begs the question whether there is a direct pathogenic link between podocytes, CRP and albuminuria. The aim of the study therefore was to examine whether podocytes produce and/or respond to CRP and whether the nature of the response could contribute to the induction of proteinuria.
Materials and methods
Unless otherwise stated all chemicals and reagents were obtained from Sigma (Poole, Dorset, UK).
Cell culture
The human podocyte line used in these experiments expresses a temperaturesensitive SV40 promoter that allows proliferative undifferentiated growth at 33°C and differentiated growth at 37°C. The cells were grown to confluence in RPMI 1640 containing 10% fetal calf serum, 100 lg/mL penicillin (Invitrogen, Paisley, Scotland, UK) and 100 lg/mL streptomycin (Invitrogen), 2 mM glutamine (Invitrogen), ITS supplement (insulin/selenium/transferrin) (Invitrogen). The cells were then transferred to 37°C and allowed to differentiate for at least 10 days. The cell lines have been previously extensively characterized and have been shown to express a number of podocytespecific differentiation markers [17] .
C-reactive protein
Native CRP was derived from ascite fluid (Biodesign, Oxford, UK). Monomeric CRP (mCRP) was made by heating the native isoform for 70°C for 1 h [18] .
In vitro experimental conditions
For most of the experiments, differentiated podocytes were exposed to native CRP at concentrations of 1 and 10 lg/mL, very approximately corresponding to moderate and elevated risk of developing heart disease. However, for some experiments, cells were exposed to additional concentrations of CRP, i.e. 0.1, 0.5, 1.0, 10 and 50 lg/mL. Podocytes were also exposed to mCRP as it has previously been reported that the monomeric form may be the biologically active form [19] . In addition, some cells were also concomitantly exposed to macrophage-conditioned medium (MCM), IL-1b (10 ng/mL) (R&D Systems, Oxford, UK), LPS (1 lg/mL) or sodium azide (15 mM). Cells were stimulated in serum-free conditions for 24 h to avoid the confounding effects of serum-borne CRP.
Preparation of MCM MCM was prepared from U937 cells as previously described [20] .
Reverse transcription-polymerase chain reaction RNA was extracted from cells using TRIzol (Invitrogen) according to the manufacturer's instructions. Aliquots of 0.5 lg total RNA were reverse transcribed using an AMV Reverse Transcription System according to manufacturer's instructions (Promega, Southampton, UK). The resulting complementary DNA was amplified using PlatinumÒTaq DNA Polymerase High fidelity (Invitrogen) and 50 pmol of specific sense and antisense primers. Thermocycling conditions were optimized for each primer set.
CRP was then amplified using specific primers: sense 5#-TCGTATGC-CACCAAGAGACAAGACA-3# and antisense 5#-AACACTTCGCCTTG-CACTTCATA-3# [21] and glyceraldehyde 3-phosphate dehydrogenase sense 5#-ACGGATTTGGTCGTATTGGG-3# antisense 5#-TGAT-TTTGGAGGGATCTCGC-3# [22] Protein preparation Proteins were prepared either by TRIzol extraction as directed by the manufacturer or by scraping the cells into 750 ll reducing sample buffer.
Protein lysates in sample buffer were not usually assayed for protein but membranes were reprobed for b-actin to normalize for loading. However, when it was necessary to measure the protein levels of cell lysates, the cells were taken up in reducing sample buffer (minus bromophenol blue) and the protein concentrations determined by Bio-Rad RC-DC assay kit according to the manufacturer's instructions.
Protein assay
Protein concentrations of samples prepared by the TRIzol method were determined by Bio-Rad DC protein assay (Bio-Rad, Hertfordshire, UK) using bovine serum albumin (BSA) standards according to the manufacturer's instructions for equal loading onto gels. [Typically, 20-lg protein were added per well for sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis].
Protein concentrations of samples prepared in reducing sample buffer (minus bromophenol blue) were determined by the Bio-Rad RC-DC protein assay using BSA standards according to the manufacturer's instructions.
Western blotting
Equal volumes of podocyte proteins were mixed with non-reducing sample buffer for CRP protein determination or reducing buffer for other proteins, boiled for 5 min then resolved on SDS-polyacrylamide gels of appropriate pore size. The gels were then blotted onto nitrocellulose membranes for 1 h at 100 V. The membranes were blocked in 5% milk protein solution in Trisbuffered saline containing 0.05% Tween 20 (TTBS) saline after which they were washed and incubated with appropriate primary antibody overnight at 4°C. After washing, the membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary antibody. Protein bands on the membrane were detected using the SuperSignal West Pico ECL reagent (Pierce, Rockford, IL). Bands were quantified on a Bio-Rad GS 700 Imaging Densitometer.
Primary antibodies used in western blotting were as follows: rabbit anti-CRP (Calbiochem, Nottingham, UK), rabbit anti-nephrin, mouse anti-FccR1 (CD64) and RII (CD 32), mouse anti-human podocalyxin-like 1, mouse antiBcl-2, mouse anti-caspase-3 (Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-b-actin, rabbit anti-podocin, rabbit anti-CD2AP (Abcam, Cambridge, UK), rabbit anti-phospho AKT, rabbit anti-total AKT (Cell Signalling Technology, Beverly, MA).
The following secondary antibodies were used in western blotting: horseradish peroxidase-conjugated goat anti-rabbit IgG (Dakocytomation, Glostrup, Denmark), horseradish peroxidase-conjugated rabbit anti-mouse IgG.
CRP enzyme-linked immunosorbent assay
The 96-well microtitre plates (Nunc, Thermo Fisher Scientific, Loughborough, UK) were coated with 70 lL rabbit anti-CRP antibody (5 lg/ mL) (Calbiochem) in 50 mM carbonate buffer pH 9.6 overnight at 4°C. The plates were washed four times with wash buffer [phosphate-buffered saline (PBS) 1 0.1% Tween 20] . Non-specific binding sites were blocked with 100 lL/well solution of 2% BSA in wash buffer for 1 h at room temperature. Fifty microlitres CRP standards from 300 to 4.7 ng/mL [serial dilutions of CRP derived from human ascite fluid (Biodesign)] or samples (culture supernatants) were incubated for 2 h at room temperature. The plates were then washed four times and incubated with a monoclonal anti-CRP antibody (AbCam) at a dilution of 1/750 for 2 h at room temperature. After a further four washes, the plates were incubated with horseradish peroxidase-conjugated rabbit anti-mouse IgG for 1.5 h at room temperature. Colour development was carried out using OPD (Invitrogen) as chromogen with H 2 O 2 as the substrate. Following colour development, the reaction was stopped using 1 M H 2 SO 4 and optical densities were measured at 492 nm on a Titertek Multiscan Plus (Titertek Instruments, Huntsville, AL).
IL-6 and tumor necrosis factor a enzyme-linked immunosorbent assay IL6 and tumor necrosis factor (TNFa) enzyme-linked immunosorbent assays (ELISAs) were carried out according to manufacturer's recommendations (DuoSet R&D systems).
Measurement of caspase-3 activity
Following treatment of cells with CRP in a 25-cm 2 flask, the cells were scraped into their culture medium (5 mL) on ice. The medium was then centrifuged at 3000 3 g for 5 min. The supernatants were discarded and the pellets resuspended in 100 lL lysis buffer (Tris-acetate buffer pH 7.4) and homogenized. The lysates were then centrifuged at 11, 600 3 g for 10 min at 4°C. The supernatants were carefully removed and analysed for protein concentration. Caspase-3 activity was detected by a modified fluorometric CaspACE TM Assay System (Promega). This assay is based on the ability of caspase-3 to cleave the fluorogenic substrate Ac-DEVD-7-amino-4-methyl coumarin (AMC). The specificity of the assay was determined using the caspase-3 inhibitor Ac-DEVD-CHO. The fluorescence of this reaction was monitored at 360 nm excitation and 460 nm emission using the Mx 4000ä Multiplex qPCR System (Stratagene). Fluorescence intensity was calibrated against standard concentrations of AMC. Caspase-3 activity was expressed as picomoles AMC per minute per microgram protein at 30°C.
Immunohistochemistry
Four hundred microlitres of a cell suspension (10 4 per well) were plated into each chamber of an eight-well Permanox slide (Lab TekÒ). The cells were incubated at 33°C for 2 days after which they were transferred to 37°C to allow them to differentiate. The podocytes were stimulated with 0, 1, 10 or 50 lg/mL CRP in serum-free medium for 24 h after which the medium was aspirated and the cells washed three times with PBS. The cells in each well were then fixed with 400 lL of 4% sucrose and 2% paraformaldehyde in PBS for 10 min. After three washes with PBS, the cells were permeabilized with 0.3% Triton X-100 in PBS for 10 min. After a further three washes, the cells were incubated for 30 min with a blocking solution (4% fetal calf serum, 0.1% Tween 20 in PBS (200 ll/well). The podocytes were then stained with FITC-conjugated phalloidin (Sigma) (5 lg/mL in 0.1% Tween 20 in PBS (30 lL/well)) for 50 min. Finally, the slides were washed in deionized water before covering the stained cells with a coverslip with a few drops of fluorescent mounting medium (Dakocytomation). The slide was allowed to dry for 30 min in the dark before being examined using confocal microscopy (Olympus FV 1000 Confocal laser scanning microscope).
Depletion of CRP
Protein-A-insoluble cell suspension (100 ll) was washed twice in PBS. Forty microlitres of a 1:4 dilution of polyclonal anti-CRP antibody was added to the protein A and incubated at room temperature for 2 h. The protein A was then washed three times with PBS. Twenty microlitres of CRP ascites solution were added to the protein A and incubated overnight at 4°C. The Protein A suspension was spun down and the 'CRP depleted' supernatant was retained.
In addition, 1 lg/mL CRP was added to podocytes in the presence of 10 lL polyclonal anti-CRP antibody (Calbiochem).
Statistics
Results are shown as means AE SEMs. A t-test was carried out to determine statistical significance between means. Where multiple comparisons between means were determined, an analysis of variance with Bonferroni correction was applied. Statistical significance was defined as P < 0.05. Representative western blots are presented. However, where appropriate, the histograms represent the densitometry and statistics carried out on all blots.
Results

Growth of podocytes in serum-free medium
In order to assess the viability of podocytes cultured in serum-free medium over time, we performed a time course from 6 to 96 h. A protein assay was carried out on the cell monolayers to assess their protein content. The data demonstrated that the protein content of the cell monolayer decreased with time ( Figure 1 ). We therefore carried out all assays at the 24 h time point.
Effect of cytokines on the production of CRP by podocytes
Podocytes were treated with the pro-inflammatory cytokine IL-1b (10 ng/mL) or with MCM both of which are known to induce the production of CRP in human aortic endothelial cells [23] . Both IL-1b and MCM induced the expression of CRP messenger RNA (mRNA) in podocytes ( Figure 2 ) but we were unable to detect the expression of CRP protein in culture supernatants or cell protein extracts by western blotting or ELISA at Day 1 or Day 3 (data not shown). To examine whether the observed effects were due to contamination with LPS or azide, podocytes were also stimulated with 1 lg/mL LPS and 15 mM sodium azide [10, 11] . These agents were unable to induce either CRP mRNA or protein in podocytes (data not shown).
Effect of CRP on podocyte cytokine production
In order to examine the effect of exogenous CRP on podocytes, CRP was added to podocyte cultures for 24 h. Podocytes were also stimulated with MCM or IL-1b (as positive controls). After 24 h, the podocyte culture supernatants were analysed for IL-6 and TNFa.
MCM and IL-1b induced podocyte IL6 secretion into culture supernatants. However, although CRP at 1 lg/mL (native and monomeric) had no effect, CRP at 10 lg/mL induced a small but significant rise in IL6 levels (P < 0.03 versus CRP 1 and CRP m ) (Figure 3 ). Only MCM, but not CRP or IL1b, induced TNFa secretion by podocytes ( Figure 3 )
Podocytes and FccR receptor expression
For CRP to exert an effect on podocytes, it would have to bind to a receptor. CRP is known to engage FccR receptors on immune cells and injured endothelial cells [24] [25] [26] [27] . We therefore carried out western blotting to determine whether podocytes expressed these receptors. Our data showed that human podocytes constitutively expressed FccRI (Figure 4 ). In contrast, FccRII receptor was barely expressed in control showing reverse transcription-polymerase chain reaction for CRP mRNA expression in podocytes exposed to MCM, 10 ng/mL IL-1b or medium alone. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the housekeeping gene to normalize for loading. cells but was up-regulated following treatment with CRP ( Figure 4 ) thus making both Fcc RI and II possible candidate receptors for active interaction with CRP on podocytes. FccRIII receptors have also been shown to bind mCRP in human neutrophils [28] . However, we were unable to detect either message or protein for these receptors on cultured human podocytes under any conditions (data not shown).
CRP and slit diaphragm protein expression
As inflammatory conditions are associated with proteinuria and since the podocyte slit diaphragm complex is thought to play a crucial role in the development of proteinuria, both structurally and via signalling pathways [29] , we examined the effects of CRP on the expression of slit diaphragm proteins nephrin, podocin and CD2AP.
Western blotting demonstrated that expression of nephrin protein was significantly up-regulated by 10 lg/mL CRP and mCRP (P < 0.05 and P < 0.009, respectively) ( Figure 5 ). CD2AP was up-regulated only by treatment with 1 lg/mL CRP (P ¼ 0.008), while podocin expression remained unaffected by CRP ( Figure 5 ).
CRP and structural protein ezrin and podocalyxin-like protein expression
As well as being a molecule pivotal in maintaining the podocyte cytoskeletal structure, ezrin has also been reported to signal cell survival [30] . Western blotting demonstrated that ezrin protein was up-regulated following treatment with 1 lg/mL CRP (P ¼ 0.001) (Figure 6 ).
Linked to the actin cytoskeleton via ezrin is podocalyxinlike protein, a major sialoglycoprotein of the polyanionic coat required for the maintenance of podocyte structure and function. Our results showed that exposure of podocytes to 1 lg/mL CRP resulted in an up-regulation of podocalyxin-like protein over control levels (P < 0.001) ( Figure 6 ).
CRP and apoptosis
Accumulating data suggests that an inability to replace podocytes lost by apoptosis is an early step in the pathological progression to proteinuria and glomerulosclerosis. Given that podocytes are terminally differentiated cells with limited regenerative capacity, prevention of podocyte apoptosis is critical for maintenance of podocyte number and glomerular function. For this reason, we examined whether CRP played a role in podocyte apoptosis.
Western blotting demonstrated that CRP reduced the intensity of the 24-and 17/19-kD active caspase-3 subunits expressed in 'control' cells ( Figure 7 ).
Bcl-2 is an anti-apoptotic protein known to inhibit the release of cytochrome c from mitochondria [31] . Bcl-2 is released from the pro-apoptotic protein Bad once the latter has been inactivated by phosphorylation with pAkt (a downstream target of PI-3 kinase) [32] . It is also transcriptionally regulated in its own right [33] . Western blotting demonstrated that Bcl-2 was up-regulated over control levels in podocytes following treatment with CRP (P < 0.05 versus medium) (Figure 8 ).
CRP and PI3 kinase
As some of the slit diaphragm proteins are known to signal via the PI-3 kinase/Akt signalling pathway and since their expression had been up-regulated by CRP, we wished to determine whether the P1-3 kinase survival pathway could be involved in the anti-apoptotic actions of CRP. To this end, podocytes were incubated with CRP in the presence or absence of the PI-3 kinase inhibitor LY294002 (LY) for 24 h.
Akt is a downstream signalling molecule of the PI-3 kinase pathway. Treatment of podocytes with CRP in the presence of LY (13 lM) resulted in a complete inhibition of Akt activation (phosphorylation) as observed by western blotting (Figure 9a ). In over 20 assays, Akt activation (phosphorylation) in the presence of CRP was generally increased ( Figure 9a ). These data, however, did not reach statistical significance, as on some occasions we observed that Akt phosphorylation was decreased in the presence of CRP.
A fluorometric CaspACEä assay not only confirmed that CRP reduced caspase-3 activity but further demonstrated that PI-3 kinase inhibition reduced the suppressive effect of CRP on caspase-3 activity (*P < 0.03 CRP 1 versus CRP 1 1LY and medium) (Figure 9b ) implicating a role for CRP in activating the PI-3 kinase pathway. However, surprisingly, addition of LY294002 appeared to reduce the caspase-3 activity in control (non-CRP treated) cells (yP < 0.05 versus med). showing expression of nephrin, podocin and CD2AP in podocyte cell lysates in response to 1 or 10 lg/mL CRP and 1 lg/mL mCRP or medium alone (nephrin: *P ¼ 0.005, **P < 0.001 versus med, n ¼ 3-9; CD2AP: *P ¼ 0.008, n ¼ 3). b-Actin was used as a loading control. Representative blots from three to five experiments are shown-histograms show the densitometric data from all blots expressed as ratios over b-actin. Western blots showing expression of structural proteins ezrin and podocalyxin-like protein-1 in podocyte cell lysates in response to 1 or 10 lg/mL CRP and 1 lg/mL mCRP or medium alone (ezrin: *P < 0.01 versus med, n ¼ 5; podocalyxin: *P < 0.001, n ¼ 3). b-Actin was used as a loading control. Representative blots are shown-histograms show the densitometric data from all blots expressed as ratios over b-actin.
When the effects of CRP in the presence of LY on caspase-3 protein expression were examined by western blotting, we unexpectedly found that the intensities of the 24-and 19/17-kD active subunit bands were markedly reduced. The control cells (no CRP) appeared to exhibit a greater downregulation of these caspase-3 activated subunits than cells treated with CRP ( Figure 10 ). However, although not always detected by western blotting, the expression of the 12-kD active subunit of caspase-3 was increased in the presence of the PI-3 kinase inhibitor ( Figure 10 ). This may account for the overall increase in caspase-3 activity measured in the cell lysates from cells treated with CRP and LY (Figure 9b ).
Specificity of CRP
In order to assess whether the observed effects of CRP were specifically due to the acute phase protein itself and not a contamination product of the ascites fluid preparation (other than azide or LPS), the ascites fluid was depleted of CRP using anti-CRP and protein A. In addition, anti-CRP antibody was added to the podocyte cultures in combination with CRP (1 lg/mL). The effects of CRP depletion and anti-CRP antibody on the expression of caspase-3 were examined by western blotting. The results demonstrated no difference in podocyte caspase-3 expression in response to depleted CRP or CRP in the presence of anti-CRP polyclonal antibody compared to control cells in serum-free medium, strongly suggesting that the observed effects were specific to the CRP protein itself (Figure 11 ).
Dose response of CRP
In the current study, the doses of CRP chosen were designed to approximately reflect normal (1 lg/mL) and chronically raised levels (10 lg/mL). In order to ascertain the extent of the dose effect, we exposed podocytes to a range of doses of CRP, i.e. 0.1, 0.5, 1.0, 10 and 50 lg/mL CRP. Western blotting demonstrated that the effects of CRP on caspase-3 protein expression appeared to follow a J shape curve with the 1 lg/mL dose exerting maximum suppression of serum-free medium-induced caspase-3 expression and 50 lg/mL CRP inducing greater activation than medium alone (Figure 12a) .
Nephrin expression showed a similar pattern but with nephrin expression peaking over the 0.5-10 lg/mL dose range (Figure 12b ).
Effects of CRP on podocyte morphology
In order to determine what effect CRP treatment had on podocyte cell morphology, podocytes were incubated with increasing concentrations of CRP for 24 h in serum-free medium. The cells were then stained with FITC-conjugated phalloidin. Examination of the slides by confocal microscopy demonstrated that there was no significant effect of any dose of CRP used (0, 1, 10 and 50 lg/mL) on the podocyte actin cytoskeleton in the 24-h time frame studied ( Figure 13 ).
Discussion
Both proteinuria and inflammation are conditions associated with elevated circulating CRP levels. However, whether chronically raised CRP levels are directly involved in the pathophysiology of proteinuria and renal disease or whether they are a marker of a continuing disease process is still a topic of controversy. The current study aimed to ascertain whether there was a direct causal link between raised CRP levels and podocyte injury, which could lead to the initiation of proteinuria.
Although the liver is known to be the major site CRP protein secretion, the kidney has also been identified as an extra-hepatic site of CRP production with renal tubular epithelial secreting this acute phase protein [34] . In the current study, we found that cultured podocytes expressed CRP mRNA although they did not appear to synthesize CRP protein under conditions, which are known to stimulate its production in endothelial cells. This was not due to a failure in the detection method as in preliminary experiments we were able to detect CRP in hepatocyte culture supernatants as well as in CRP-spiked culture medium. It is also unlikely that this was due to insufficient time for protein translation as after 3 days one would expect to see a response to treatment given the rapid increase in CRP levels in vivo following acute exposure to infection. It may be due to the absence of a secondary signal required for initiation of protein translation.
The cytokine response of podocytes to CRP was somewhat underwhelming as we were only able to detect a small increase in IL6 levels following exposure to 10 lg/mL CRP, while TNFa was not detected at all. CRP is able to engage a number of ligands depending on the context of its action. These include phosphocholine on pathogenic bacteria [35] , nuclear antigens [36] , C1q to activate the classical complement pathway [37] and the Fcc receptors [38] . Studies with CRP have shown interaction with both FccRI and RII receptors in man and mouse. The ability to engage both activating and regulatory receptors may explain why CRP can have both pro-and anti-inflammatory actions. We were able to detect both FccRI and FccRII receptors in podocytes, while FccRIII receptors were not detectable at either message or protein level. However, we cannot say at this stage whether these are the receptors responsible for the observed effects of CRP in podocytes. Nephrin is a podocyteassociated protein which plays a key role in maintaining the interpodocyte slit diaphragm structure and thereby the permselective properties of the glomerular filtration barrier. Although nephrin protein expression is known to be downregulated in patients suffering from albuminuria [39] , we found that in podocytes, nephrin expression was upregulated by the higher concentration of CRP. The nephrin/podocin/CD2AP complex not only controls the structure of the slit diaphragm but is also involved in cell signalling. Both nephrin and CD2AP are known to interact with the p85 regulatory subunit of PI-3 kinase to stimulate PI-3 kinasedependent Akt signalling in podocytes [29] . Akt activation mediates the subsequent phosphorylation and inactivation of several target proteins in podocytes including the proapoptotic protein Bad thereby protecting podocytes against detachment-induced cell death [40] . As well as changes in nephrin and CD2AP, we also observed an up-regulation of the plasma membrane protein ezrin and podocalyxin-like protein. Ezrin has also been reported to protect LLC-PK1 cells from apoptosis by activating the PI-3 kinase/Akt pathway [30] , while podocalyxin has been shown to exhibit anti-apoptotic properties in malignant cells, probably via its interaction with ezrin [41] .
That apoptosis is suppressed by CRP was confirmed by the observed reduction of caspase-3 activity and the increased expression of Bcl-2 [31] . Bcl-2 is known to have a protective anti-apoptotic role, as down-regulation of this protein is closely associated with the development of progressive glomerular injury. Low Bcl-2 expression levels are also a clinical prognostic indicator of poor renal outcome patients with IgA nephropathy [42] .
In our study, the observed raised levels of caspase-3 activity in control cells was almost certainly a function of the serum-free cell culture conditions that were necessary to avoid the confounding effects of CRP in the serum. The effects of serum-free culture conditions on podocytes have previously been described [43, 44] and suggest that podocytes cultured in serum-free conditions inherently express a pro-apoptotic phenotype.
Treatment of podocytes with the PI-3 kinase inhibitor LY reversed the suppressive effect of CRP on caspase-3 activity as determined by the fluorometric caspase-3 activity assay. This suggests that the CRP-induced decrease in caspase-3 activity is mediated via the PI-3 kinase pathway. However, why LY reduced caspase-3 activity in control cells, when it increased it in CRP-treated cells is not known at this stage. It is possible that in the absence of an active PI-3 kinase pathway to inhibit, LY may have other secondary effects, which lead to the observed decrease in caspase-3 activity. Also puzzling is the fact that despite increasing caspase-3 activity in CRP-treated cells, LY unexpectedly appeared to reduce the intensity of the 24-and 17/19-kD subunits (as seen by western blotting). Moreover, this reduction was most marked in the control cells (no CRP). As the PI-3 kinase-Akt signalling pathway acts as a survival (anti-apoptotic) pathway, it is surprising to observe a reduction in active caspase-3 subunits in the presence of a PI-3 kinase inhibitor (which should enhance apoptosis). It is possible that the small 12-kD subunit, which was increased on LY treatment, may have inherent caspase-3 activity. However, in control cells the 12-kD subunit activity in the absence of the larger subunits results in an overall decrease in caspase-3 activity as detected by the fluorimetric assay. This phenomenon clearly requires further investigation but is beyond the scope of the current study.
Akt phosphorylation, although generally up-regulated by CRP (as seen in over 20 assays), was not consistently observed. A counterintuitive down-regulation of Akt phosphorylation in the face of decreased apoptosis has been previously observed by Foster et al. [43] who found that vascular endothelial growth factor was able to suppress apoptosis in serumstarved podocytes while concomitantly reducing AKT phosphorylation.
Although we have demonstrated that apoptosis is downregulated by treatment with CRP, this is the opposite of what occurs in endothelial cells where apoptosis is increased [45] and is one of the mechanisms thought to be involved in CRP's induction of cardiovascular disease.
Evidence for a relationship between CRP and cell survival has already previously been demonstrated. In cancer cells for example, CRP has been shown to bind Fcc receptors, activate PI-3 kinase /Akt and inhibit caspase cascade activation induced by chemotherapy drugs [46] . However, while CRPmediated podocyte survival is desirable, CRP-induced survival of malignant cells is not.
A study by Pepys group found that of 468 samples of serum from normal adult individuals, 90% had levels <3 lg/mL and 99% had levels <10 lg/mL [47] . Moreover, joint guidelines from the Centres for Disease Control and Prevention and the American Heart Association have set guidelines for the use of CRP levels as an indicator of cardiovascular risk at <1.0 lg/mL as low, 1-3 lg/mL as moderate and >3 lg/mL as high risk [48] . To what extent the culture conditions of our study with the two CRP concentrations (1and 10 lg/mL) in serum-free media for 24 h actually reflect the glomerular milieu to which the podocytes are exposed in vivo normally and during chronic low-grade inflammation is difficult to assess. However, our study demonstrates that of the two concentrations of CRP, the 1 lg/mL concentration most consistently appears able to modulate the expression of podocyte-specific proteins and signalling molecules in a positive cytoprotective manner. Raised levels (10 lg/mL) do not appear to exert as much protection. In fact, our study demonstrated that, with respect to caspase-3 expression, the effects of CRP appeared to follow a 'J-shape' curve with the 1 lg/mL dose exerting most suppression and the 50 lg/mL CRP inducing greater activation than medium alone. These data may explain why subjects with chronically raised CRP levels in the higher range are more prone to suffer from cardiovascular problems and proteinuria as their protection levels (at least with respect to podocytes) are reduced while low circulating levels of CRP (coincident with median serum levels) appear to be actively protective.
With the exception of the up-regulatory effect of mCRP on nephrin protein expression, this isoform of CRP was generally less effective in eliciting cytoprotective responses in podocytes than the native form, although no detrimental effect was identified. This is in contrast to what has been reported in neutrophils where the monomeric, and not the native form, exerts anti-apoptotic actions [49] .
In further support of a lack of CRP-induced-negative effects on podocytes, we did not observe any CRP-induced changes to the actin cytoskeleton even at the 50 lg/mL dose.
In the light of the data presented in this study, CRP does not appear to play an obvious adverse pathogenic role in podocyte biology, at least at low levels, but rather appears to promote podocyte survival by inhibiting apoptosis. Under normal circumstances, podocytes are in a quiescent nonproliferative state and have a limited ability to perform controlled re-entry into the mitotic cycle. Consequently, when podocytes are reduced in number, as a result of injury, they are not replaced, an event which normally leads to the development of proteinuria and glomerulosclerosis. While chronically raised CRP levels may cause damage to the endothelium, the response of the podocytes on the Bowman's capsule side of the glomerular basement membrane may be to counteract this adverse effect. Whether the observed response of the podocytes to CRP is that of selfpreservation or whether CRP plays an active role in podocyte protection is yet to be fully determined. Fig. 13 . Effect of CRP on podocyte morphology. Cells grown on permanox slides were exposed to increasing concentration of CRP for 24 h. The podocyte actin cytoskeleton was stained with FITC-phalloidin. Representative photomicrographs from three experiments are presented (3400 magnification).
